Blood Test Flags 78% 10-Year Alzheimer's Risk in Healthy Adults
Updated
Updated · Newsweek · Jul 15
Blood Test Flags 78% 10-Year Alzheimer's Risk in Healthy Adults
3 articles · Updated · Newsweek · Jul 15
Summary
Nearly 2,700 cognitively healthy adults showed that very high p-tau217 levels signaled a 78% chance of cognitive impairment within 10 years and a 38% risk within five years.
The JAMA study, presented at AAIC 2026 in London, found the single-protein blood marker added predictive power beyond brain scans and genetic testing alone.
Moderately elevated p-tau217 still carried notable risk—about 15% over five years and 45% over 10 years—though researchers said age, genetics, kidney function, obesity and race can affect results.
The test is already FDA-cleared in the U.S. for aiding Alzheimer's diagnosis, and experts said it could move risk screening into primary care and speed prevention-trial recruitment.
Doctors also warned that without a cure, positive results could bring anxiety, insurance concerns and unequal access, underscoring the need for counseling and broader validation.
A new blood test can predict your Alzheimer's risk. Is this a medical breakthrough or just a new way to worry?
We can now detect Alzheimer's plaques with a blood test. But does removing them actually stop memory loss?
FDA-Cleared Blood Tests Revolutionize Alzheimer’s Diagnosis: Early Detection, Clinical Impact, and Future Directions (2025-2026)
Overview
In 2025, the FDA cleared the first blood test for detecting amyloid plaques, marking a major breakthrough in Alzheimer's diagnosis. This test, the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, uses a simple blood draw, making diagnosis earlier, less invasive, and much more accessible for millions of Americans. By reducing patient discomfort and improving access, the new test allows for earlier intervention in the disease process. This shift promises to transform how Alzheimer's is detected and managed, offering hope for better patient outcomes and easier access to care.